TABLE 2

RRs and 95% CIs for type 2 diabetes according to vitamin E and placebo groups, WHS

Follow-up interval (years)Vitamin E (n = 19,347)Placebo (n = 19,369)RR (95% CI)*P value
End of study8278690.95 (0.87–1.05)0.31
    1–291871.05 (0.78–1.41)0.76
    3–41511830.83 (0.67–1.03)0.08
    5–61761970.89 (0.73–1.09)0.27
    7–81661631.02 (0.82–1.26)0.87
    9–102152091.03 (0.85–1.24)0.78
    11–1228300.94 (0.56–1.57)0.80
0–5 follow-up years4184670.90 (0.79–1.02)0.10
≥6 follow-up years4094021.02 (0.89–1.17)0.81
Excluding first 2 years7367820.94 (0.85–1.04)0.24
Excluding first 5 years4965040.98 (0.87–1.11)0.79
Compliance analyses5395810.93 (0.83–1.04)0.21
Compliance analyses4995250.95 (0.84–1.07)0.36
  • *

    * Adjusted for age and randomized assignment of aspirin and β-carotene.

  • Sensitivity analysis; censored when patient stopped reporting taking at least two-thirds of vitamin E or placebo pills.

  • Censored when patient stopped reporting taking at least two-thirds of vitamin E or placebo pills or if they were taking four out-of-trial vitamin E pills per month.